Carboplatin Pharmachemie Dosage/Direction for Use

Notes: Carboplatin Injection does not contain any antimicrobial preservative; it is intended for single-dose administration only. Any carboplatin solution remaining 12 hours (when stored at room temperature) or 36 hours (when stored in a refrigerator) after dilution with the recommended diluents, must be discarded. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Administration: This preparation is intended for intravenous use only, usually by an infusion lasting 15 minutes or longer. It may be given to outpatients since hydration is not required. Aluminum reacts with carboplatin causing precipitate formation and loss of potency, therefore, needles or intravenous sets containing aluminum parts that may come in contact with the drug must not be used for the preparation or administration of carboplatin.
Dosage: Advanced Ovarian Carcinoma: Initial Treatment: In patients with advanced ovarian carcinoma, carboplatin administered in combination therapy as established by specialists, is recommended at a dosage of 300 mg/m² i.v. on day 1 every 4 weeks for six cycles.
Secondary Treatment: Carboplatin, as monotherapy, has been shown to be effective in patients with recurrent ovarian carcinoma. The recommended dosage is 360 mg/m² i.v. on day 1 every 4 weeks.
Dosage Adjustment: Reduction of the initial dosage by 20-25% is recommended for those patients who present with risk factors such as prior myelosuppressive treatment and low performance status (ECOG-Zubrod 2-4 or Karnofsky below 80).
Determination of the hematological nadir by weekly blood counts during the initial courses of treatment with carboplatin is recommended for future dosage adjustment.
Patients with Renal Function Impairment: Patients with creatinine clearance values below 60 ml/min. are at increased risk of severe bone marrow suppression. In renally-impaired patients who received single-agent carboplatin therapy, the incidence of severe leukopenia, neutropenia, or thrombocytopenia, has been about 25% when the dosage modifications in the following table have been used. (See table.)

Click on icon to see table/diagram/image

These dosing recommendations apply to the initial course of treatment. Subsequent dosages should be adjusted according to the patient's tolerance, based on the degree of bone marrow suppression.
In general, intermittent courses of carboplatin should not be repeated until the neutrophil count is at least 2,000 cells/mm³ and platelet count is at least 100,000 cells/mm³.